This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Infinity Pharmaceuticals Inc. (INFI - Snapshot Report) reported a loss of $1.15 per share in the fourth quarter of 2012, wider than the year-ago loss of 53 cents and the Zacks Consensus Estimate of a loss of 89 cents. The wider loss during the quarter was primarily due to the absence of revenues.
Infinity Pharma did not generate any revenue during fourth quarter; however, it recorded $22.3 million as collaborative research and development revenue in the year-ago quarter.
Infinity Pharma suffered a loss of $3.18 per share for the full year 2012, wider than the Zacks Consensus Estimate of a loss of $1.32 and the year-ago loss of $1.50 per share. The company recorded full-year revenues of $47.1 million, down 49.2% year over year. Infinity Pharma’s 2012 revenues edged past the Zacks Consensus Estimate of $47 million.
Infinity Pharma’s research and development (R&D) expenses increased 33.9% to $40 million in the fourth quarter of 2012. R&D expenses during the quarter increased primarily due to the restructuring agreement with Millennium in Dec 2012. The company’s general and administrative (G&A) expenses increased 17.7% to $7.1 million.
Infinity Pharma is developing retaspimycin hydrochloride (HCl), which is under the company’s heat shock protein 90 (Hsp90) inhibitor program. The company will be reporting data from two studies on the candidate in the first half of 2013. One is in combination with Sanofi’s (SNY - Analyst Report) Taxotere (docetaxel) and the other one is in combination with Novartis’ (NVS - Snapshot Report) Afinitor (everolimus).
The company is also progressing with its phosphoinositide-3-kinase (PI3K) program. The company is expecting several data read-outs and trial initiations under this program this year.
In Jan 2013, Infinity Pharma had announced its financial guidance for 2013. The company expects to incur around $115 million–$125 million as operating expenses in 2013. Infinity Pharma expects net loss for the year also in the range of $115 million to $125 million.
The company expects to exit 2013 with cash and investments of about $210 million–$220 million. Infinity Pharma believes with its current cash position, it can easily fund its operations till 2015.
Infinity Pharma currently carries a Zacks Rank #3 (Hold). Other stocks such as BioDelivery Sciences International Inc. (BDSI - Snapshot Report), with a Zacks Rank #2 (Buy), currently looks more attractive in the pharma space.